Obsidian Therapeutics, Inc.
OBX
$18.68
-$0.05-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 4.59M | 4.55M | 5.31M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 26.14M | 20.28M | 28.26M | ||
| Operating Income | -26.14M | -20.28M | -28.26M | ||
| Income Before Tax | -25.86M | -19.63M | -26.90M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -25.86M | -19.63M | -26.90M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -25.86M | -19.63M | -26.90M | ||
| EBIT | -26.14M | -20.28M | -28.26M | ||
| EBITDA | -25.85M | -19.94M | -27.89M | ||
| EPS Basic | -1.19 | -316.54 | -1.93 | ||
| Normalized Basic EPS | -0.74 | -197.84 | -1.21 | ||
| EPS Diluted | -1.19 | -316.54 | -1.93 | ||
| Normalized Diluted EPS | -0.74 | -197.84 | -1.21 | ||
| Average Basic Shares Outstanding | 21.81M | 62.00K | 13.94M | ||
| Average Diluted Shares Outstanding | 21.81M | 62.00K | 13.94M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||